These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19212884)

  • 1. Balanced 2(n) factorial designs when observations are spatially correlated.
    Sethuraman V; Raghavarao D
    J Biopharm Stat; 2009; 19(2):332-44. PubMed ID: 19212884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balanced two-stage designs for phase II clinical trials.
    Ye F; Shyr Y
    Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technical note: Designing and analyzing quantitative factorial experiments.
    St-Pierre NR; Weiss WP
    J Dairy Sci; 2009 Sep; 92(9):4581-8. PubMed ID: 19700721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serially balanced designs for two sets of treatments.
    Altan S
    J Biopharm Stat; 2005; 15(2):279-82. PubMed ID: 15796295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications.
    Dejaegher B; Heyden YV
    J Pharm Biomed Anal; 2011 Sep; 56(2):141-58. PubMed ID: 21632194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractional factorial designs for legal psychology.
    Stolle DP; Robbennolt JK; Patry M; Penrod SD
    Behav Sci Law; 2002; 20(1-2):5-17. PubMed ID: 11979488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical limit to trials needed in one-person randomized controlled experiments.
    Alemi R; Alemi F
    Qual Manag Health Care; 2007; 16(2):130-4. PubMed ID: 17426611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying the permutation test to factorial designs.
    Mewhort DJ; Johns BT; Kelly MA
    Behav Res Methods; 2010 May; 42(2):366-72. PubMed ID: 20479168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and analysis of experiments.
    Shuster JJ
    Methods Mol Biol; 2007; 404():235-59. PubMed ID: 18450053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
    Dutta S; Zhang Y
    Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factorial and time course designs for cDNA microarray experiments.
    Glonek GF; Solomon PJ
    Biostatistics; 2004 Jan; 5(1):89-111. PubMed ID: 14744830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
    Baek I; Zhu W; Wu X; Wong WK
    J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal crossover designs for logistic regression models in pharmacodynamics.
    Waterhouse TH; Eccleston JA; Duffull SB
    J Biopharm Stat; 2006; 16(6):881-94. PubMed ID: 17146986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossover designs with correlated observations.
    Donev AN
    J Biopharm Stat; 1998 May; 8(2):249-62. PubMed ID: 9598421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioavailability of four modified-release ursodeoxycholic acid preparations for once-a-day administration.
    Simoni P; Sabatini L; Baraldini M; Mirasoli M; Roda A; Roda E
    Int J Clin Pharmacol Res; 2002; 22(2):37-45. PubMed ID: 12503774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.